Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: Results from 3 phase III studies

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 4, 2013, Pages 377-384

  Duvic, Madeleine ^a   Geskin, Larisa ^b   Prince, H Miles ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Fusion protein; Mycosis fungoides; S zary syndrome

Indexed keywords

DENILEUKIN DIFTITOX; INTERLEUKIN 2 RECEPTOR ALPHA; PLACEBO;

ARTICLE; CANCER PATIENT; CANCER STAGING; CAPILLARY LEAK SYNDROME; COUGHING; CUTANEOUS T CELL LYMPHOMA; DEMOGRAPHY; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; FATIGUE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HYPOTENSION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); RIGOR; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

FUSION PROTEIN; MYCOSIS FUNGOIDES; SÉZARY SYNDROME;

ANTINEOPLASTIC AGENTS; DIPHTHERIA TOXIN; FEMALE; HUMANS; INTERLEUKIN-2; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84880731408     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.02.020     Document Type: Article

References (20)

1. A.C. Hristov, E.C. Vonderheid, and M.J. Borowitz Simplified flow cytometric assessment in mycosis fungoides and Sezary syndrome Am J Clin Pathol 136 2011 944 953
2. E. Olsen, E. Vonderheid, and N. Pimpinelli Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) Blood 110 2007 1713 1722 (Pubitemid 47443880)
3. G.W. Jones, D. Rosenthal, and L.D. Wilson Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome) Cancer 85 1999 1985 1995 (Pubitemid 29202774)
4. Y.H. Kim, S. Chow, and A. Varghese Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides Arch Dermatol 135 1999 26 32 (Pubitemid 29069513)
5. Y.H. Kim, H.L. Liu, and S. Mraz-Gernhard Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome Arch Dermatol 139 2003 857 866
6. Y.H. Kim, G. Martinez, and A. Varghese Topical nitrogen mustard in the management of mycosis fungoides Arch Dermatol 139 2003 165 173
7. E.N. Mostow, S.L. Neckel, and L. Oberhelman Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA Arch Dermatol 129 1993 747 752 (Pubitemid 23172779)
8. S. Rupoli, G. Goteri, and S. Pulini Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides Eur J Haematol 75 2005 136 145 (Pubitemid 41008284)
9. U. Wollina, R. Dummer, and N.H. Brockmeyer Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma Cancer 98 2003 993 1001 (Pubitemid 37022100)
10. E.C. Vonderheid, E.T. Tan, and A.F. Kantor Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma J Am Acad Dermatol 20 1989 416 428 (Pubitemid 19086776)
11. N.S. Agar, E. Wedgeworth, and S. Crichton Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal J Clin Oncol 28 2010 4730 4739
12. P. Bacha, D.P. Williams, and C. Waters Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein J Exp Med 167 1988 612 622 (Pubitemid 18073658)
13. C.A. Waters, P.A. Schimke, and C.E. Snider Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells Eur J Immunol 20 1990 785 791 (Pubitemid 20167033)
14. D.P. Williams, C.E. Snider, and T.B. Strom Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells J Biol Chem 265 1990 11885 11889
15. E. Olsen, M. Duvic, and A. Frankel Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma J Clin Oncol 19 2001 376 388 (Pubitemid 32112849)
16. H.M. Prince, M. Duvic, and A. Martin Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma J Clin Oncol 28 2010 1870 1877
17. A. Negro-Vilar, H.M. Prince, and M. Duvic Efficacy and safety of denileukin difitox (Dd) in cutaneous T-cell lymphoma (CTCL) patients: integrated analysis of three large phase III trials J Clin Oncol 26 suppl 15S 2008 (abstract 8551)
18. H.M. Prince, M. Duvic, and A. Martin Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sezary syndrome receiving placebo J Am Acad Dermatol 67 2012 867 875
19. H.M. Prince, A.G. Martin, and E.A. Olsen Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sezary syndrome Leuk Lymphoma 54 2013 69 75
20. Ontak [package insert] 2011 Eisai Medical Research Inc Woodcliff Lake, NJ